CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 123 enrolled
Drug / intervention
Etoricoxib 90 mg + diacerein 50 mg +1 moredrug
Likely dose
Etoricoxib 90 mg + diacerein 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07549386
NCT07549386Phase 3Completed

Efficacy and Safety of Etoricoxib 90 mg + Diacerein 50 mg Capsule Compared to Meloxicam 15 mg + Diacerein 50 mg in Patients With Knee and/or Hip Osteoarthritis: A Phase III, Controlled, Randomized, Double-blind, Multicenter Clinical Trial.

Laboratorios Liomont·interventional·Posted Apr 24, 2026·Updated Apr 29, 2026

In Brief

A Phase 3 clinical trial evaluating Etoricoxib 90 mg + diacerein 50 mg and Meloxicam 15 mg + diacerein 50 mg for Pain Management and Osteoarthritis. Completed, enrolled 123 participants across 4 sites.

Detailed Summary

The goal of this clinical trial is to learn if fixed-dose combination etoricoxib 90 mg + diacerein 50 mg capsule works to treat knee/hip osteoarthritis-associated pain in adults. It will also learn about the safety of the drug. The main questions it aims to answer are: Does etoricoxib+diacerein reduce pain intensity as per WOMAC scale after 60 days? What medical problems do participants have when taking etoricoxib 90 mg+diacerein 50 mg capsule for 60 days? Researchers will compare the test drug etoricoxib 90 mg+diacerein 50 mg capsule to an active comparator (meloxicam 15 mg + diacereina 50 mg) to see if drug ABC works to treat pain in patients with osteoarthritis. Participants will: Take drug the test or comparator drugs every day for 60 days. Visit the clinic once a month for health and outcomes follow-up. Keep a diary of their symptoms, pain intensity, WOMAC scale, adverse events, rescue medication use, other used drugs, and treatment adherence.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesMexico
CollaboratorsEPIC Research CRO

Timeline

Phase 3CompletedFinished
20252026
First PostedApr 24, 2026
Enrollment StartMay 24, 2024
Primary CompletionMar 27, 2025
Study CompletionOct 15, 2025
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 2 months ago

Interventions

Etoricoxib 90 mg + diacerein 50 mgdrug

Once a day for 60 days

Meloxicam 15 mg + diacerein 50 mgdrug

Once a day for 60 days.